Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report

EGFR mutations are the most important drivers of gene alterations in lung adenocarcinomas and are sensitive to EGFR-TKIs. However, resistance to EGFR-TKIs is inevitable in the majority of EGFR-mutated lung cancer patients. Numerous resistant mechanisms have been revealed to date, and more are still...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Xu, Ziyi, Xie, Tongji, Xing, Puyuan, Ying, Jianming, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403890/
https://www.ncbi.nlm.nih.gov/pubmed/36033496
http://dx.doi.org/10.3389/fonc.2022.937282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403890/
https://www.ncbi.nlm.nih.gov/pubmed/36033496
http://dx.doi.org/10.3389/fonc.2022.937282

Ejemplares similares